Silicone Migration From Baked-on Silicone Layers. Particle Characterization in Placebo and Protein Solutions.
暂无分享,去创建一个
Stefanie Funke | Hanns-Christian Mahler | Wolfgang Friess | W. Friess | K. Bechtold-Peters | Karoline Bechtold-Peters | Julia Matilainen | Heiko Nalenz | Julia Matilainen | Stefanie Funke | Heiko Nalenz | Hanns-Christian Mahler | Karoline Bechtold-Peters
[1] Jared S. Bee,et al. Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces. , 2013, Journal of pharmaceutical sciences.
[2] W. Friess,et al. Analysis of thin baked-on silicone layers by FTIR and 3D-Laser Scanning Microscopy. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[3] R. Narwal,et al. Cross-linked silicone coating: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics. , 2014, Journal of pharmaceutical sciences.
[4] W. Jiskoot,et al. Flow Imaging Microscopy for Protein Particle Analysis—A Comparative Evaluation of Four Different Analytical Instruments , 2013, The AAPS Journal.
[5] Huub Schellekens,et al. Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.
[6] Theodore W Randolph,et al. Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions. , 2010, Journal of pharmaceutical sciences.
[7] D. K. Sharma,et al. Micro-Flow Imaging: Flow Microscopy Applied to Sub-visible Particulate Analysis in Protein Formulations , 2010, The AAPS Journal.
[8] Bill Pikounis,et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. , 2011, Biologicals : journal of the International Association of Biological Standardization.
[9] Theodore W Randolph,et al. Excipient effects on humanized monoclonal antibody interactions with silicone oil emulsions. , 2012, Journal of pharmaceutical sciences.
[10] Dean C Ripple,et al. Protein particles: what we know and what we do not know. , 2012, Journal of pharmaceutical sciences.
[11] Jared S. Bee,et al. Gelation of a monoclonal antibody at the silicone oil-water interface and subsequent rupture of the interfacial gel results in aggregation and particle formation. , 2015, Journal of pharmaceutical sciences.
[12] B. Matthews,et al. Accurate calculation of the density of proteins. , 2000, Acta crystallographica. Section D, Biological crystallography.
[13] J. Carpenter,et al. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. , 2013, Journal of pharmaceutical sciences.
[14] Matt Trau,et al. A comparative study of submicron particle sizing platforms: accuracy, precision and resolution analysis of polydisperse particle size distributions. , 2013, Journal of colloid and interface science.
[15] Wim Jiskoot,et al. Particles in therapeutic protein formulations, Part 1: overview of analytical methods. , 2012, Journal of pharmaceutical sciences.
[16] Patrick Garidel,et al. Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development , 2010, Pharmaceutical Research.
[17] Y. Maa,et al. Syringe Siliconization Process Investigation and Optimization , 2012, PDA Journal of Pharmaceutical Science and Technology.
[18] P. Kolhe,et al. Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches , 2011, AAPS PharmSciTech.
[19] Tapan K. Das. Protein Particulate Detection Issues in Biotherapeutics Development—Current Status , 2012, AAPS PharmSciTech.
[20] A. Koulov,et al. Discrimination Between Silicone Oil Droplets and Protein Aggregates in Biopharmaceuticals: A Novel Multiparametric Image Filter for Sub-visible Particles in Microflow Imaging Analysis , 2011, Pharmaceutical Research.
[21] Michael J Akers,et al. Excipient-drug interactions in parenteral formulations. , 2002, Journal of pharmaceutical sciences.
[22] D. Volkin,et al. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[23] J. Carpenter,et al. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins. , 2015, Journal of pharmaceutical sciences.
[24] Hui Zhao,et al. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). , 2010, Journal of pharmaceutical sciences.
[25] Dean C Ripple,et al. The Use of Index-Matched Beads in Optical Particle Counters , 2014, Journal of research of the National Institute of Standards and Technology.
[26] R. Ingle,et al. Pre-filled syringe – a ready-to-use drug delivery system: a review , 2014, Expert opinion on drug delivery.
[27] Brian M. Murphy,et al. Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.
[28] J. Carpenter,et al. Albinterferon α2b adsorption to silicone oil-water interfaces: effects on protein conformation, aggregation, and subvisible particle formation. , 2014, Journal of pharmaceutical sciences.
[29] Stephan O. Krause,et al. Characterization of the Initial Level and Migration of Silicone Oil Lubricant in Empty Prefilled Syringes for Biologics Using Infrared Spectroscopy , 2014, PDA Journal of Pharmaceutical Science and Technology.
[30] C. R. Middaugh,et al. Silicone oil induced aggregation of proteins. , 2005, Journal of pharmaceutical sciences.
[31] Y. Maa,et al. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. , 2012, Journal of pharmaceutical sciences.
[32] Randall J Mrsny,et al. Formulation and delivery issues for monoclonal antibody therapeutics. , 2006, Advanced drug delivery reviews.
[33] Basant Sharma,et al. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. , 2007, Biotechnology advances.
[34] A. Koulov,et al. Factors Governing the Precision of Subvisible Particle Measurement Methods – A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe , 2015, Pharmaceutical Research.
[35] Jared S. Bee,et al. Effects of surfaces and leachables on the stability of biopharmaceuticals. , 2011, Journal of pharmaceutical sciences.
[36] Theodore W Randolph,et al. Protein aggregation and particle formation in prefilled glass syringes. , 2014, Journal of pharmaceutical sciences.
[37] A. Rosenberg,et al. Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.
[38] A. Pekar,et al. Opalescent Appearance of an IgG1 Antibody at High Concentrations and Its Relationship to Noncovalent Association , 2004, Pharmaceutical Research.
[39] Kiichi Fukui,et al. Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins , 2014, Journal of pharmaceutical sciences.
[40] S. Shire,et al. Characterization of Particles in Protein Solutions: Reaching the Limits of Current Technologies , 2010, The AAPS Journal.
[41] Gregory A. Sacha,et al. Pre-filled syringes: a review of the history, manufacturing and challenges , 2015, Pharmaceutical development and technology.
[42] Igor Polikarpov,et al. Average protein density is a molecular‐weight‐dependent function , 2004, Protein science : a publication of the Protein Society.
[43] A. Polozova,et al. Practical Considerations for Detection and Characterization of Sub-Micron Particles in Protein Solutions by Nanoparticle Tracking Analysis , 2015, PDA Journal of Pharmaceutical Science and Technology.
[44] A. Mire-Sluis,et al. Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation. , 2010, Biologicals : journal of the International Association of Biological Standardization.
[45] W. Jiskoot,et al. Micro-flow imaging and resonant mass measurement (Archimedes)--complementary methods to quantitatively differentiate protein particles and silicone oil droplets. , 2013, Journal of pharmaceutical sciences.
[46] Vincent J. Sullivan,et al. Evaluation of the effect of syringe surfaces on protein formulations. , 2011, Journal of pharmaceutical sciences.
[47] S. Bakri,et al. Intravitreal Silicone Oil Droplets After Intravitreal Drug Injections , 2008, Retina.
[48] W. Friess,et al. Optimization of the bake-on siliconization of cartridges. Part I: Optimization of the spray-on parameters. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[49] B. Sharma. Immunogenicity of therapeutic proteins. Part 1: impact of product handling. , 2007, Biotechnology advances.
[50] Stephen Gomez,et al. On developing a process for conducting extractable-leachable assessment of components used for storage of biopharmaceuticals. , 2010, Journal of pharmaceutical sciences.
[51] S. Singh,et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.
[52] D. Volkin,et al. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. , 2010, Journal of pharmaceutical sciences.
[53] Jared S. Bee,et al. Production of particles of therapeutic proteins at the air–water interface during compression/dilation cycles , 2012 .
[54] W. Jiskoot,et al. Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges. , 2016, Journal of pharmaceutical sciences.
[55] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[56] B. Sharma. Immunogenicity of therapeutic proteins. Part 2: impact of container closures. , 2007, Biotechnology advances.
[57] Hanns-Christian Mahler,et al. The potential clinical relevance of visible particles in parenteral drugs. , 2012, Journal of pharmaceutical sciences.
[58] M. Kahook,et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. , 2011, Investigative ophthalmology & visual science.
[59] R. Barer,et al. Refractive Index of Concentrated Protein Solutions , 1954, Nature.
[60] Michael J Akers,et al. Practical fundamentals of glass, rubber, and plastic sterile packaging systems , 2010, Pharmaceutical development and technology.
[61] T. Spitznagel,et al. Demonstrating the stability of albinterferon alfa-2b in the presence of silicone oil. , 2011, Journal of pharmaceutical sciences.
[62] J. Philo. Is any measurement method optimal for all aggregate sizes and types? , 2006, The AAPS Journal.
[63] P. Mangiagalli,et al. Silicone-oil-based subvisible particles: their detection, interactions, and regulation in prefilled container closure systems for biopharmaceuticals. , 2012, Journal of pharmaceutical sciences.
[64] Hanns-Christian Mahler,et al. Forced degradation of therapeutic proteins. , 2012, Journal of pharmaceutical sciences.
[65] Theodore W Randolph,et al. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. , 2009, Journal of pharmaceutical sciences.
[66] Wei Wang,et al. Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.
[67] W. Friess,et al. Optimization of the bake-on siliconization of cartridges. Part II: Investigations into burn-in time and temperature. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[68] Wei Wang,et al. Impact of residual impurities and contaminants on protein stability. , 2014, Journal of pharmaceutical sciences.
[69] Steven Kozlowski,et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.
[70] Hanns-Christian Mahler,et al. Surface activity of a monoclonal antibody. , 2009, Journal of pharmaceutical sciences.
[71] J. Ježek,et al. Biopharmaceutical formulations for pre-filled delivery devices , 2013, Expert opinion on drug delivery.
[72] Susumu Uchiyama,et al. Liquid formulation for antibody drugs. , 2014, Biochimica et biophysica acta.
[73] Vladimir I Razinkov,et al. Accelerated Formulation Development of Monoclonal Antibodies (mAbs) and mAb-Based Modalities , 2015, Journal of biomolecular screening.
[74] Vasco Filipe,et al. Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates , 2010, Pharmaceutical Research.
[75] Chi-Ting Huang,et al. Quantitation of protein particles in parenteral solutions using micro-flow imaging. , 2009, Journal of pharmaceutical sciences.
[76] P. Surmann,et al. The fate of silicone oil during heat-curing glass siliconization--changes in molecular parameters analyzed by size exclusion and high temperature gas chromatography. , 2000, PDA journal of pharmaceutical science and technology.
[77] Marisa K Joubert,et al. Classification and Characterization of Therapeutic Antibody Aggregates , 2011, The Journal of Biological Chemistry.
[78] S. Shire,et al. Issues and Challenges of Subvisible and Submicron Particulate Analysis in Protein Solutions , 2012, The AAPS Journal.
[79] Jörg Huwyler,et al. Determination of the Density of Protein Particles Using a Suspended Microchannel Resonator. , 2015, Journal of pharmaceutical sciences.
[80] G. Winter,et al. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis. , 2013, Journal of pharmaceutical sciences.
[81] Theodore W Randolph,et al. Effect of the siliconization method on particle generation in a monoclonal antibody formulation in pre-filled syringes. , 2015, Journal of pharmaceutical sciences.